Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
A snapshot of the year-to-date total market return for 2024, outlining performance drivers and practical implications for investors.
28,420 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Curious about riding the AI chip boom without placing a big bet on a single stock? This guide shows how ETFs can help...
What could turn a biotech bet into a life-changing gain? This article breaks down how to spot this millionaire-maker ...
Investors confront a cooling AI rally as Rambus faces growth deceleration and valuation pressures, signaling a potent...
Investors are weighing how Coeur Mining performed in Q4 2025 and what it means for coeur mining (cde) 2025. This view...
Volatility can create buying opportunities. Here's one hypergrowth tech stock 2026 pick that blends AI momentum, scal...
Finding value in semiconductors is tough, but a disciplined approach can spot opportunities amid rapid tech change. L...
A notable fund exited its position in a medical device stock, locking in gains as the shares slipped over the past ye...
Micron Technology jumped on a bold target upgrade, lifting questions about sustainability as the AI memory cycle fuel...
CrowdStrike has become a pillar in AI-era cybersecurity, but a 14% decline raises the question: is it a buy? This gui...
Markets can feel unsettled, but history favors investors who stick to a proven plan. Learn the one move that has help...
As debt pressures mount, Ray Dalio warns the stock market may be flirting with bubble-like extremes seen before the 1...